Daniel Atar

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Journal: Journal for immunotherapy of cancer
Published: April 20, 2026

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.

Journal: Science translational medicine
Published: March 06, 2024

Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.

Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.

Journal: Leukemia
Published: January 30, 2024

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.

Journal: JAMA
Published: June 27, 2023

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.

Journal: International journal of molecular sciences
Published: September 23, 2022

Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation.

Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation.

Journal: Haematologica
Published: August 25, 2022

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas.

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas.

Journal: Biomedicines
Published: August 03, 2022

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.

Journal: Oncoimmunology
Published: June 10, 2022

Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation.

Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy
Published: March 02, 2022

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.

Journal: Frontiers in immunology
Published: April 02, 2021

CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.

CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.

Journal: Briefings in functional genomics
Published: September 30, 2019

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.

Journal: Oncoimmunology
Published: August 10, 2019
Showing 1-12 of 12

Last Updated: 09/26/2026